Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Saad, 2012, Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer, Urologic Oncol, 30, 369, 10.1016/j.urolonc.2010.08.007 O’Connor, 2007, DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents, Br J Cancer, 96, 189, 10.1038/sj.bjc.6603515 Charles-Edwards, 2006, Diffusion-weighted magnetic resonance imaging and its application to cancer, Cancer Imag, 6, 135, 10.1102/1470-7330.2006.0021 Padhani, 2010, Multiparametric imaging of tumor response to therapy, Radiology, 256, 348, 10.1148/radiol.10091760 Harry, 2010, Use of new imaging techniques to predict tumour response to therapy, Lancet Oncol, 11, 92, 10.1016/S1470-2045(09)70190-1 Heijmen, 2012, Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?, Crit Rev Oncol/Hematol, 83, 194, 10.1016/j.critrevonc.2011.12.008 Biffar, 2010, Measurement of perfusion and permeability from dynamic contrast-enhanced MRI in normal and pathological vertebral bone marrow, Magn Reson Med, 64, 115, 10.1002/mrm.22415 Biswal, 2007, Molecular imaging: integration of molecular imaging into the musculoskeletal imaging practice, Radiology, 244, 651, 10.1148/radiol.2443060295 Daldrup-Link, 2007, MR imaging of therapy-induced changes of bone marrow, Eur Radiol, 17, 743, 10.1007/s00330-006-0404-1 Lecouvet, 2013, MRI for response assessment in metastatic bone disease, Eur Radiol, 23, 1986, 10.1007/s00330-013-2792-3 Messiou, 2009, Imaging metastatic bone disease from carcinoma of the prostate, Br J Cancer, 101, 1225, 10.1038/sj.bjc.6605334 Messiou, 2014, Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values, Skeletal Radiol, 43, 205, 10.1007/s00256-013-1768-3 Pearce, 2012, Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI, Br J Radiol, 85, 1102, 10.1259/bjr/30649204 Lecouvet, 2010, Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), Eur Radiol, 20, 2973, 10.1007/s00330-010-1879-3 Lecouvet, 2007, Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940 Messiou, 2010, Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring, Cancer Biomarkers, 6, 21, 10.3233/CBM-2009-0116 Bonekamp, 2012, Oncologic applications of diffusion-weighted MRI in the body, J Magn Reson Imag, 35, 257, 10.1002/jmri.22786 Messiou, 2011, Assessing response in bone metastases in prostate cancer with diffusion weighted MRI, Eur Radiol, 21, 2169, 10.1007/s00330-011-2173-8 Wu, 2011, Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis, J Magn Reson Imaging, 34, 128, 10.1002/jmri.22608 Lecouvet, 2009, Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases?, Radiology, 252, 624, 10.1148/radiol.2522090263 Eiber, 2014, Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions, J Nucl Med, 55, 191, 10.2967/jnumed.113.123646 Linden, 2006, Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer, J Clin Oncol, 24, 2793, 10.1200/JCO.2005.04.3810 Gemignani, 2013, Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer, J Nucl Med, 54, 1697, 10.2967/jnumed.112.113373 van Kruchten, 2012, PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma, J Nucl Med, 53, 182, 10.2967/jnumed.111.092734 Larson, 2004, Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer, J Nucl Med, 45, 366 Afshar-Oromieh, 2014, Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imag, 41, 11, 10.1007/s00259-013-2525-5 Kähkönen, 2013, In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548, Clin Cancer Res, 19, 5434, 10.1158/1078-0432.CCR-12-3490 Ndlovu, 2010, Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies?, Nucl Med Commun, 31, 659, 10.1097/MNM.0b013e3283399107 Sharma, 2012, Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management, Nucl Med Commun, 33, 139, 10.1097/MNM.0b013e32834e3b14 Talbot, 2011, Diagnosis of bone metastasis: recent comparative studies of imaging modalities, Q J Nucl Med Mol Imag, 55, 374 Zhang, 2013, Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignancies, Nucl Med Commun, 34, 451, 10.1097/MNM.0b013e32835fa552 Yang, 2011, Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy, Eur Radiol, 21, 2604, 10.1007/s00330-011-2221-4 Helyar, 2010, The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate, Eur J Nucl Med Mol Imag, 37, 706, 10.1007/s00259-009-1334-3 Chakraborty, 2013, Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma, Clin Nucl Med, 38, 616, 10.1097/RLU.0b013e31828da5cc Even-Sapir, 2006, The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT, J Nucl Med, 47, 287 Hetzel, 2003, F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management, J Bone Miner Res, 18, 2206, 10.1359/jbmr.2003.18.12.2206 Bourguet, 2003, Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose (FDP-PET scanning) in oncology (2002), Br J Cancer, 89, S84, 10.1038/sj.bjc.6601088 Evangelista, 2012, Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging, Biomed Pharmacother, 66, 448, 10.1016/j.biopha.2012.06.004 Banwait, 2011, The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia, Am J Hematol, 86, 567, 10.1002/ajh.22044 Chan, 2012, Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients, J Nucl Med, 53, 1730, 10.2967/jnumed.112.104893 Damle, 2013, The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan, Jpn J Radiol, 31, 262, 10.1007/s11604-013-0179-7 Kruger, 2009, Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT, Eur J Nucl Med Mol Imag, 36, 1807, 10.1007/s00259-009-1181-2 Langsteger, 2011, Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading, Q J Nucl Med Mol Imag, 55, 448 Balogova, 2013, 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type, Eur J Nucl Med Mol Imag, 40, 943, 10.1007/s00259-013-2342-x Costelloe, 2012, Fast Dixon whole-body MRI for detecting distant cancer metastasis: a preliminary clinical study, J Magn Reson Imaging, 35, 399, 10.1002/jmri.22815 Ghanem, 2002, Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton, Eur J Radiol, 43, 256, 10.1016/S0720-048X(01)00477-6 Brown, 1998, T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy, Clin Radiol, 53, 493, 10.1016/S0009-9260(98)80168-2 Saip, 1999, Response evaluation of bone metastases in breast cancer: value of magnetic resonance imaging, Cancer Invest, 17, 575, 10.3109/07357909909032842 Ciray, 2001, Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging, Acta Radiol, 42, 198, 10.1080/028418501127346503 Tombal, 2005, Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, Prostate, 65, 178, 10.1002/pros.20280 Graham, 2014, Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib, J Natl Cancer Inst, 106, dju033, 10.1093/jnci/dju033 Lee, 2007, An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone, Cancer Res, 67, 3524, 10.1158/0008-5472.CAN-06-4236 Rozel, 2009, Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model, J Cell Biochem, 107, 58, 10.1002/jcb.22056 Bauerle, 2010, Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis, Eur J Radiol, 73, 280, 10.1016/j.ejrad.2008.10.020 Reischauer, 2010, Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps – initial observations, Radiology, 257, 523, 10.1148/radiol.10092469 Byun, 2013, Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma, J Nucl Med, 54, 1053, 10.2967/jnumed.112.115964 Blackledge, 2014, Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study, PLoS ONE, 9, e91779, 10.1371/journal.pone.0091779 Montemurro, 2004, Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy, Acta Radiol, 45, 71, 10.1080/02841850410003374 Budde, 2012, Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI, Clin Exp Metastasis, 29, 51, 10.1007/s10585-011-9428-2 Vassiliou, 2010, Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria, Br J Cancer, 103, 925, 10.1038/sj.bjc.6605825 Lee, 2007, A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone, Neoplasia, 9, 1003, 10.1593/neo.07954 Padhani, 2014, Therapy monitoring of skeletal metastases with whole-body diffusion MRI, J Magn Reson Imaging, 39, 1049, 10.1002/jmri.24548 Coleman, 2012, Effects of bone-targeted agents on cancer progression and mortality, J Natl Cancer Inst, 104, 1059, 10.1093/jnci/djs263 Rosen, 2003, Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, J Clin Oncol, 21, 3150, 10.1200/JCO.2003.04.105 Mitsui, 2012, Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer, BJU Int, 110, E628, 10.1111/j.1464-410X.2012.11355.x Brown, 2012, Computer-aided quantitative bone scan assessment of prostate cancer treatment response, Nucl Med Commun, 33, 384, 10.1097/MNM.0b013e3283503ebf Coleman, 1988, Bone scan flare predicts successful systemic therapy for bone metastases, J Nucl Med, 29, 1354 Coleman, 1988, Osteocalcin: a potential marker of metastatic bone disease and response to treatment, Eur J Cancer Clin Oncol, 24, 1211, 10.1016/0277-5379(88)90130-7 Scher, 1987, Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors, Am J Med, 82, 6, 10.1016/0002-9343(87)90483-9 Coleman, 1988, Biochemical prediction of response of bone metastases to treatment, Br J Cancer, 58, 205, 10.1038/bjc.1988.194 Pollen, 1984, The flare phenomenon on radionuclide bone scan in metastatic prostate cancer, AJR Am J Roentgenol, 142, 773, 10.2214/ajr.142.4.773 Ryan, 2011, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response, Clin Cancer Res, 17, 4854, 10.1158/1078-0432.CCR-11-0815 DeMeo, 1991, Etidronate sodium therapy – a cause of poor skeletal radiopharmaceutical uptake, Semin Nucl Med, 21, 332, 10.1016/S0001-2998(05)80136-9 Roudier, 2003, Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results, Clin Exp Metastasis, 20, 171, 10.1023/A:1022627421000 Cook, 2011, 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin), EJNMMI Res, 1 Wade, 2006, Flare response in 18F-fluoride ion PET bone scanning, AJR Am J Roentgenol, 186, 1783, 10.2214/AJR.05.0225 Installe, 2005, (18)F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone, J Nucl Med, 46, 1650 Balogova, 2013, Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake, Clin Nucl Med, 38, 200, 10.1097/RLU.0b013e31827a2294 Avery, 2013, 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound, Clin Nucl Med, 38, 746, 10.1097/RLU.0b013e3182996138 Cachin, 2006, Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy, J Clin Oncol, 24, 3026, 10.1200/JCO.2005.04.6326 Stafford, 2002, Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy, Acad Radiol, 9, 913, 10.1016/S1076-6332(03)80461-0 Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 Wahl, 2009, From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307 Thacker, 2012, 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib, Cancer Med, 1, 230, 10.1002/cam4.33 Skougaard, 2013, Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab, J Nucl Med, 54, 1026, 10.2967/jnumed.112.111757 Katayama, 2012, Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers, Ann Nucl Med, 26, 426, 10.1007/s12149-012-0595-2 Huyge, 2010, Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients, Clinl Oncol(R Coll Radiol), 22, 818, 10.1016/j.clon.2010.05.021 Mortimer, 2001, Metabolic flare: indicator of hormone responsiveness in advanced breast cancer, J Clin Oncol, 19, 2797, 10.1200/JCO.2001.19.11.2797 Mortazavi-Jehanno, 2012, Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study, Eur J Nucl Med Mol Imag, 39, 450, 10.1007/s00259-011-1981-z Balogova, 2013, FCH PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone – a pilot study, Nuklearmedizin, 52, A124 Gabriel, 2009, 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy, J Nucl Med, 50, 1427, 10.2967/jnumed.108.053421 Gordon, 1990, Skeletal assessment in neuroblastoma – the pitfalls of iodine-123-MIBG scans, J Nucl Med, 31, 129 Troncone, 1990, The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience, Eur J Nucl Med, 16, 325, 10.1007/BF00842788 Pfluger, 2003, Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma, AJR Am J Roentgenol, 181, 1115, 10.2214/ajr.181.4.1811115 Leboulleux, 2008, Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy, J Clin Endocrinol Metabol, 93, 3021, 10.1210/jc.2008-0459 Lebtahi, 1999, Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy, J Nucl Med, 40, 1602 Zuetenhorst, 2002, Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease, Nucl Med Commun, 23, 735, 10.1097/00006231-200208000-00006 Timmers, 2012, Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography, J Natl Cancer Inst, 104, 700, 10.1093/jnci/djs188 Kenny, 2008, Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients, J Nucl Med, 49, 879, 10.2967/jnumed.107.049452 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Fox, 2011, Developing imaging strategies for castration resistant prostate cancer, Acta Oncol, 50, 39, 10.3109/0284186X.2011.572914 Mulders, 2009, Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer, Prostate Cancer Prostatic Dis, 12, 241, 10.1038/pcan.2009.25 Fitzpatrick, 2014, Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel, Eur J Cancer, 50, 1617, 10.1016/j.ejca.2014.03.010 Kwee, 2007, Cancer imaging with fluorine-18-labeled choline derivatives, Semin Nucl Med, 37, 420, 10.1053/j.semnuclmed.2007.07.003 Linton, 2012, Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost?, Eur Urol, 62, 76, 10.1016/j.eururo.2012.02.059 Gaeta, 2013, Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers, Q J Nucl Med Mol Imag, 57, 352 Ashton, 2013, Advanced MR techniques in multicenter clinical trials, J Magn Reson Imaging, 37, 761, 10.1002/jmri.23799